Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + pomalidomide + sintilimab for relapsed/refractory DLBCL (Phase II, China)
ChiCTR2400084099Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, pomalidomide and sintilimab in diffuse large B-cell lymphoma (DLBCL), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
bendamustinepomalidomidesintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400084099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084099.